Global Antibody Drug Conjugates (ADC) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Customize Your Report Customize Your Report Buy Now Buy Now Free Sample Report Free Sample Report
Home Medical Devices Global Antibody Drug Conjugates Market
Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Antibody Drug Conjugates (ADC) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

  • Medical Devices
  • Published Report
  • Dec 2024
  • Global
  • 350 Pages
  • No of Tables: 643
  • No of Figures: 62
Buy Now Buy Now

Global Antibody Drug Conjugates Market

Market Size in USD Billion

CAGR :  % Diagram

Chart Image USD 9.33 Billion USD 29.69 Billion 2024 2031
Diagram Forecast Period
 2024 –2031
Diagram Market Size (Base Year)
 USD 9.33 Billion
Diagram Market Size (Forecast Year)
 USD 29.69 Billion
Diagram CAGR
 %
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Request For Unlock

Global Antibody Drug Conjugates (ADC) Market Segmentation, By Product (Enhertu, Kadcyla, Trodelvy, Polivy, Adcetris, Padcev, Besponsa, Elahere, Zylonta, Mylotarg, Tivdak, and Others), Antigen Component (HER2 Receptor, Trop-2, CD79B, CD30, Nectin 4, CD22, CD19, CD33, Tissue Factors, and Others), Antibody Component (Third Generation ADCs, Second Generation ADCs, Fourth Generation ADCs, and First Generation ADCs), Linkers Component (Cleavable Linkers and Non Cleavable Linkers), Cytotoxic Payloads or Warheads Component (DNA Damaging Agents and Microtubule Disrupting Agents), Linker Technology (Peptide Linkers, Thioether Linkers, Hydrazone Linkers, and Disulfide Linkers), Conjugation Technology (Site-Specific Conjugation and Chemical Conjugation), Indication (Breast Cancer, Blood Cancer (Leukemia, Lymphoma), Lung Cancer, Gynecological Cancer, Gastrointestinal Cancer, Genitourinary Cancer, and Others), End User (Hospitals, Specialty Center, Clinics, Ambulatory Centers, Home Healthcare, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) - Industry Trends and Forecast to 2031

Antibody Drug Conjugates (ADC) Market

Antibody Drug Conjugates (ADC) Market Analysis

In May 2024, according to the data published by National Cancer Institute, in 2024, the U.S. is projected to see 2 million new cancer cases and 611,720 deaths. Leading cancers include breast, prostate, lung, colorectal, and melanoma. Prostate, lung, and colorectal cancers will comprise 48% of male cases, while breast, lung, and colorectal will make up 51% for women. The annual incidence rate is 440.5 per 100,000 people, with a mortality rate of 146.0 per 100,000. Among children and adolescents (0-19), 14,910 are expected to be diagnosed, with 1,590 deaths. The rising number of FDA approvals for ADCs and growing clinical trials highlight the market's potential. However, challenges such as high manufacturing costs and complex production processes may impact growth. Overall, the North American ADC market is poised for substantial development, supported by technological advancements and increasing adoption in oncology treatments.

Antibody Drug Conjugates (ADC) MarketAntibody Drug Conjugates (ADC) Market

Antibody Drug Conjugates (ADC) Market Size

Global Antibody Drug Conjugates (ADC) market size was valued at USD 9.33 billion in 2023 and is projected to reach USD 29.69 billion by 2031, with a CAGR of 15.6% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Antibody Drug Conjugates (ADC) Market Trends

“Advances in Antibody-Drug Conjugate (ADC) Technology”

Advances in antibody-drug conjugate (ADC) technology are driving growth in the global ADC market by enhancing both treatment effectiveness and safety in cancer care. Key innovations trends include improved linkers for stable, precise drug delivery that targets cancer cells while sparing healthy tissue. Next-generation ADCs with optimized payloads and biomarker-driven patient selection ensure that therapies reach those who will benefit most, minimizing side effects. In addition, improved manufacturing processes are lowering production costs, increasing access, and encouraging greater investment in ADC development, all contributing to a robust pipeline and expanding market interest.

Report Scope and Antibody Drug Conjugates (ADC) Market Segmentation         

Attributes

Antibody Drug Conjugates (ADC) Key Market Insights

Segments Covered
  • By Product: Enhertu, Kadcyla, Trodelvy, Polivy, Adcetris, Padcev, Besponsa, Elahere, Zylonta, Mylotarg, Jiydak, and Others
  • By Antigen Component: HER2 Receptor, Trop-2, CD79B, CD30, Nectin 4, CD22, CD19, CD33, Tissue Factors, and Others
  • By Antibody Component: First Generation ADCs, Second Generation ADCs, Third Generation ADCs, and Fourth Generation ADCs
  • By Linkers Component: Cleavable Linkers and Non-Cleavable Linkers
  • By Cytotoxic Payloads or Warheads Component: DNA Damaging Agents and Microtubule Disrupting Agents
  • By Linker Technology: Peptide Linkers, Thioether Linkers, Hydrazone Linkers, and Disulfide Linkers
  • By Conjugation Technology: Site-Specific Conjugation and Chemical Conjugation
  • By Indication: Breast Cancer, Blood Cancer (Leukemia, Lymphoma), Lung Cancer, Gynecological Cancer, Gastrointestinal Cancer, Genitourinary Cancer, and Others
  • By End User: Hospitals, Specialty Centers, Clinics, Ambulatory Centers, Home Healthcare, and Others
  • By Distribution Channel: Direct Tenders, Retail Sales, and Other

Countries Covered

U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Austria, Ireland, Poland, Norway, Hungary, Lithuania, Rest of Europe, Japan, China, India, Australia, Singapore, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, and Rest of Middle East and Africa

Key Market Players

DAIICHI SANKYO COMPANY, LIMITED (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (U.S.), Astellas Pharma Inc. (Japan), Takeda (Japan), Pfizer Inc. (U.S.), Abbvie (U.S.), ADC Therapeutics (Switzerland), Amgen, Inc. (California), AstraZeneca (England), Bayer (Germany), Byondis (Netherlands), EISAI INC (Japan), GSK plc (UK), Johnson & Johnson Services, Inc. (U.S.), Oxford BioTherapeutics (England), Remegen (China), Sanofi (France), and Sutra Biopharma, Inc. (U.S.)

Market Opportunities

  • Growing Oncology Pipeline for Antibody Drug Conjugates (ADCS) 
  • Increasing Investment in Cancer Research

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Antibody Drug Conjugates (ADC) Market Definition

Antibody-Drug Conjugates (ADCs) are targeted cancer therapies that combine an antibody with a potent anti-cancer drug. The antibody specifically binds to cancer cell markers, delivering the drug directly to cancer cells while minimizing impact on healthy cells. This precision reduces side effects and increases the drug’s effectiveness in treating cancer.

Antibody Drug Conjugates (ADC) Market Dynamics

Drivers  

  • Increasing Prevalence of Cancer

The rising prevalence of cancer significantly drives the North America Antibody-Drug Conjugates (ADC) market, increasing demand for targeted, effective treatments. ADCs offer precise cancer cell targeting with reduced harm to healthy tissues by combining monoclonal antibodies with potent cytotoxic drugs. As cancer rates climb, pharmaceutical companies are investing heavily in ADC technology to meet the need for more personalized treatments, especially for challenging cancer types. This growth in the cancer patient population accelerates ADC clinical trials, regulatory approvals, and commercial launches, further advancing the ADC market.

For instance,

In February 2024, according to an article published by WHO, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths, with 53.5 million people alive within five years of diagnosis. Lung cancer was the most common (2.5 million cases, 12.4%), followed by breast (2.3 million, 11.6%), colorectal (1.9 million, 9.6%), prostate (1.5 million, 7.3%), and stomach cancers (970,000, 4.9%). One in five people will develop cancer, with predictions of over 35 million new cases by 2050—a 77% increase. This rising incidence drives market growth for targeted cancer therapies.

The rising prevalence of cancer significantly boosts the North America ADC market by increasing the demand for targeted, effective therapies. ADCs, with their ability to deliver potent treatments directly to cancer cells while sparing healthy tissue, have gained attention as a promising solution. This growing cancer burden drives research, development, and investment in ADC technology, pushing forward new advancements and expanding the market

  • Advances in Antibody-Drug Conjugate (ADC) Technology

Advances in antibody-drug conjugate (ADC) technology are driving growth in the global ADC market by enhancing both treatment effectiveness and safety in cancer care. Key innovations include improved linkers for stable, precise drug delivery that targets cancer cells while sparing healthy tissue. Next-generation ADCs with optimized payloads and biomarker-driven patient selection ensure that therapies reach those who will benefit most, minimizing side effects. Additionally, improved manufacturing processes are lowering production costs, increasing access, and encouraging greater investment in ADC development, all contributing to a robust pipeline and expanding market interest.

For instance,

In October 2023, according to the article published in Acta Pharmaceutica Sinica B, recent progress in ADC research focuses on developing safer, more potent payloads. Key advancements include stronger cytotoxic drugs, stable linkers for precise delivery, and novel payloads like DNA-damaging and immune-modulating agents. These innovations expand the therapeutic window, reducing off-target toxicity and improving effectiveness against resistant tumors, shaping next-gen ADCs.

Innovations such as enhanced linker systems and effective drug payloads improve the precision and safety of cancer treatments. Biomarker-guided strategies enhance patient targeting for optimal efficacy. Improved manufacturing techniques have made ADCs more accessible and cost-effective, attracting investment and expanding therapy options. Overall, these advancements boost ADC effectiveness and stimulate market growth and interest from the pharmaceutical industry

Antibody Drug Conjugates (ADC) Market

Opportunities

Growing Oncology Pipeline for Antibody Drug Conjugates (ADCS) 

The oncology pipeline for Antibody Drug Conjugates (ADCs) is rapidly expanding, offering significant market potential. Numerous ADC candidates are in various stages of development, driven by advancements in tumor biology and the need for targeted therapies.

Pharmaceutical and biotech companies are heavily investing in new ADCs to enhance efficacy and safety for a range of cancers, including solid tumors and hematological malignancies. Innovations in linker technology, payloads, and antibody engineering are resulting in more effective and less toxic ADCs, broadening treatment options and attracting investor interest.

For instance,

In August 2024, according to the article published by Johnson & Johnson Innovation LLC, Johnson & Johnson's growing pipeline of antibody-drug conjugate (ADC) therapeutics and active collaborations demonstrate a strong commitment to the ADC sector. Their emphasis on innovative, safe, and effective cancer treatments showcases the transformative potential of ADCs. These initiatives foster industry partnerships, enhancing development and accessibility, and creating substantial growth opportunities in the North America ADC market.

  • Increasing Investment in Cancer Research

Increasing investment in cancer research presents a significant opportunity for the growth of the global antibody-drug conjugate (ADC) market. As governments, private organizations, and philanthropic entities prioritize effective cancer treatments, this funding becomes essential for advancing innovative ADC therapies.

These investments allow researchers to deepen their understanding of tumor biology and the mechanisms of drug action, which is critical for developing more targeted and effective ADCs. Additionally, enhanced funding facilitates larger and more diverse clinical trials, improving insights into patient responses and accelerating the evaluation and approval processes for promising ADC candidates.

For Instance,

In October 2024, according to the article published in UKRI, Innovate UK and OLS are investing USD 5.19 million in six projects under the advancing precision medicines competition, part of the Life Sciences Vision Cancer Mission. This significant funding underscores the growing commitment to cancer research and development. Such investments pave the way for innovative therapies, including antibody-drug conjugates (ADCs), creating a valuable opportunity for growth in the global ADC market.

Restraints/Challenges

  • High Development Cost & Manufacturing Complexities

The extensive investment needed for research—including innovative linker design, selecting cytotoxic agents, and optimizing conjugation techniques—substantially increases costs. The intricate manufacturing process requires precise drug-antibody attachment and rigorous quality control, further driving up expenses. In addition, specialized facilities and equipment needed for safe and efficient production add financial burdens, making it difficult for smaller biotech firms to pursue ADC development and limiting larger companies to a few projects at a time. As a result, while ADCs offer promising targeted cancer therapies, these issues restrict market growth and the introduction of new treatments.

For instance,

In July 2024, according to the article published by Journal of Antibody Drug Conjugates, Bristol Myers Squibb (BMS) made an upfront payment of USD 800 million to license Systimmune's EGFR x HER3 bispecific ADC, BL-B01D1 (Zalontamab brengitecan), currently in Phase 1 in the US and Phase 3 in China. While BL-B01D1 shows promising safety and efficacy in heavily pretreated metastatic solid tumors, the high investment costs are a concern. In addition, developing bispecific ADCs presents challenges, such as selecting the appropriate antibody format, which often requires creating two stable cell lines. This complexity increases manufacturing costs and complicates assay development

High development costs and manufacturing complexities significantly hinder the growth of the North America antibody-drug conjugates (ADC) market. The substantial financial investment required for research and the intricate manufacturing processes contribute to elevated production expenses. This complexity not only necessitates rigorous quality control measures but also demands specialized facilities and equipment, further straining resources. As a result, smaller biotech companies may be discouraged from entering the market, while even larger firms may limit their ADC initiatives.

  • Safety and Toxicity Issues of Antibody Drug Conjugates

Safety and toxicity concerns are major restraints on the growth of the global Antibody Drug Conjugates (ADC) market. Despite their design to target cancer cells, ADCs can adversely affect healthy tissues due to their potent cytotoxic payloads, leading to systemic toxicity and side effects such as neutropenia and organ-specific toxicities. Additionally, unpredictable immune responses may cause allergic reactions or immunogenicity, limiting their use in certain patient populations. The risk of off-target effects, where ADCs impact non-cancerous cells with similar antigens, further complicates treatment.

For instance,

In June 2021, according to the news release published by Elsevier, off-target toxicities are a major cause of dose-limiting side effects in antibody-drug conjugates (ADCs), primarily due to linker-drug instability and premature payload release. This narrow therapeutic index necessitates thorough safety assessments during preclinical and clinical stages. Improving testing methods and understanding safety profiles are crucial for optimizing ADCs' therapeutic potential.

Safety and toxicity concerns present major challenges for the global ADC market, as potent cytotoxic agents can lead to severe side effects, including blood disorders and organ-specific toxicities. The risk of immune reactions and off-target effects complicates their safe use, necessitating rigorous clinical testing and regulatory oversight.

Antibody Drug Conjugates (ADC) Market Scope

The market is segmented on the basis of product, antigen component, antibody component, linkers component, cytotoxic payloads or warheads component, linker technology, conjugation technology, indication, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Enhertu
  • Kadcyla
  • Podelvy
  • Adcetris
  • Padcev
  • Besponsa
  • Elahere
  • Zylonta
  • Mylotarg
  • Tivdak
  • Others

Antigen Component

  • HER2 Receptor
  • Trop-2
  • Cd79b
  • Cd30
  • Nectin 4
  • Cd22
  • Cd19
  • Cd33
  • Tissue Factors
  • Others

Antibody Component

  • Third Generation ADCs
  • Second Generation ADCs
  • Fourth Generation ADCs
  • First Generation ADCs

Linkers Component

  • Cleavable Linkers
    • Peptide Based
    • Acid Sensitive or Acid Labile
    • Glutathione Sensitive Disulfide
  • Non Cleavable Linkers

Cytotoxic Payloads or Warheads Component

  • DNA Damaging Agents
    • Camptothecin
    • Calicheamicin
    • Pyrrolobenzodiazepines
  • Microtubule Disrupting Agents
    • Auristatin
    • Maytansinoids

Linker Technology

  • Peptide Linkers
  • Thioether Linkers
  • Hydrazone Linkers
  • Disulfide Linkers

Conjugation Technology

  • Site-Specific Conjugation
  • Chemical Conjugation

Indication

  • Breast Cancer
  • Blood Cancer (Leukemia, Lymphoma)
  • Lung Cancer
  • Gynecological Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Others

End User

  • Hospitals
  • Specialty center
  • Clinics
  • Ambulatory centers
  • Home healthcare
  • Others

Distribution Channel

  • Direct tenders
  • Retail sales
    • Hospital pharmacy
    • Retail pharmacy
    • Online pharmacy
  • Others

Antibody Drug Conjugates (ADC) Market

Antibody Drug Conjugates (ADC) Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, product, antigen component, antibody component, linkers component, cytotoxic payloads or warheads component, linker technology, conjugation technology, indication, end user, and distribution channel as referenced above.

The country covered in the market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Belgium, Netherlands, Switzerland, Austria, Ireland, Poland, Norway, Hungary, Lithuania, Rest of Europe, Japan, China, India, Australia, Singapore, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, and Rest of Middle East and Africa.

North America is expected to dominate the market due to its advanced healthcare infrastructure, high demand for innovative medical devices, and a strong focus on quality and patient care.

North America is expected to be the fastest growing due to increasing adoption of advanced healthcare technologies, rising chronic disease prevalence, and a growing emphasis on cost-effective long-term vascular access solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Antibody Drug Conjugates (ADC) Market

Antibody Drug Conjugates (ADC) Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Antibody Drug Conjugates (ADC) Market Leaders Operating in the Market Are:

  •  Daiichi Sankyo Company, Limited (Japan)
  • F. Hoffmann-La Roche Ltd (Genentech) (Switzerland)
  • Gilead Sciences, Inc. (U.S.)
  • Astellas Pharma Inc. (Japan)
  • Takeda (Japan)
  • Pfizer Inc. (U.S.)
  • Abbvie (U.S.)
  • ADC Therapeutics (Switzerland)
  • Amgen, Inc. (U.S.)
  • AstraZeneca (U.K.)
  • Bayer (Germany)
  • Byondis (Netherlands)
  • EISAI INC (Japan)
  • GSK plc (U.K.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Oxford Big Therapeutics (U.K.)
  • Remegen (China)
  • Sanofi (France)
  • Sutra Biopharma (U.S.)

Latest Developments in Antibody Drug Conjugates (ADC) Market

  • In October 2024, Daiichi Sankyo and AstraZeneca's ENHERTU has received conditional approval in China as the first HER2-directed therapy for adult patients with HER2 mutant metastatic non-small cell lung cancer (NSCLC). This approval, based on positive results from the DESTINY-Lung02 and DESTINY-Lung05 studies, highlights ENHERTU's efficacy in previously treated patients. This marks the fourth indication for ENHERTU in China across various tumor types, enhancing the companies' oncology portfolio and addressing a significant unmet need in lung cancer treatment
  • In August 2024, Bayer and NextRNA Therapeutics have announced a collaboration and license agreement to develop small molecule therapeutics targeting long non-coding RNAs (lncRNAs) in oncology, offering a novel approach to disrupt lncRNA-RBP interactions in disease treatment
  • In March 2023, Roche announced its collaboration with Eli Lilly to develop the Elecsys Amyloid Plasma Panel. This innovative blood test aimed to facilitate earlier Alzheimer’s diagnosis, addressing significant barriers and improving access to timely treatments for patients
  • In January 2022, Roche launched the cobas pulse system, an innovative handheld blood glucose management device. It combined advanced digital capabilities with user-friendly design, simplifying workflows for healthcare professionals and enhancing patient care in various settings

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

Sample Image Click on image to enlarge
  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTER’S FIVE FORCES

4.3 PESTEL ANALYSIS

5 COST STRUCTURE ANALYSIS OF ANTIBODY-DRUG CONJUGATE (ADC) MANUFACTURING

5.1 ANTIBODIES

5.1.1 OVERVIEW OF ANTIBODY PRODUCTION

5.1.1.1 IN-HOUSE VS. OUTSOURCED:

5.1.2 ANTIBODY PRICING FACTORS

5.2 LINKERS

5.2.1 ROLE AND TYPES OF LINKERS

5.2.1.1 COST IMPACT BY LINKER TYPE:

5.3 CYTOTOXIC AGENTS

5.3.1 COST CONSIDERATIONS:

5.3.2 BUFFERS AND SOLVENTS

5.4 COST BREAKDOWN BY MANUFACTURING STAGE

5.4.1 PRE-PRODUCTION COSTS

5.4.2 CONJUGATION PROCESS

5.4.3 PURIFICATION AND FILTRATION

5.4.4 QUALITY CONTROL

5.5 COST PROJECTIONS AND PRICING TRENDS (2024–2030)

5.5.1 PROJECTED COST FLUCTUATIONS

5.5.2 COST IMPACT OF SCALABILITY

5.6 SUPPLIER AND GEOGRAPHIC PRICING TRENDS

5.6.1 GEOGRAPHIC COST VARIATIONS

5.6.2 SUPPLIER ANALYSIS

5.6.3 CONCLUSION

6 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF CANCER

7.1.2 ADVANCES IN ANTIBODY-DRUG CONJUGATE (ADC) TECHNOLOGY

7.1.3 INCREASING DEMAND FOR TARGETED THERAPIES

7.1.4 ADVANCEMENTS IN PROTEOMICS AND GENOMICS RESEARCH

7.2 RESTRAINTS

7.2.1 HIGH DEVELOPMENT COST & MANUFACTURING COMPLEXITIES

7.2.2 SAFETY AND TOXICITY ISSUES OF ANTIBODY DRUG CONJUGATES

7.3 OPPORTUNITIES

7.3.1 GROWING ONCOLOGY PIPELINE FOR ANTIBODY DRUG CONJUGATES (ADCS)

7.3.2 INCREASING INVESTMENT IN CANCER RESEARCH

7.3.3 INCREASING COLLABORATION WITH RESEARCH INSTITUTIONS FOR ANTIBODY DRUG CONJUGATES

7.4 CHALLENGES

7.4.1 CLINICAL TRIAL FAILURES FOR ANTIBODY DRUG CONJUGATES DEVELOPMENT

7.4.2 LENGTHY CLINICAL TRIALS AND DEVELOPMENT PHASES

8 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 ENHERTU

8.3 KADCYLA

8.4 TRODELVY

8.5 POLIVY

8.6 ADCETRIS

8.7 PADCEV

8.8 BESPONSA

8.9 ELAHERE

8.1 ZYLONTA

8.11 MYLOTARG

8.12 TIVDAK

8.13 OTHERS

9 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT

9.1 OVERVIEW

9.2 HER2 RECEPTOR

9.3 TROP-2

9.4 CD79B

9.5 CD30

9.6 NECTIN 4

9.7 CD22

9.8 CD19

9.9 CD33

9.1 TISSUE FACTORS

9.11 OTHERS

10 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT

10.1 OVERVIEW

10.2 THIRD GENERATION ADCS

10.3 SECOND GENERATION ADCS

10.4 FOURTH GENERATION ADCS

10.5 FIRST GENERATION ADCS

11 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT

11.1 OVERVIEW

11.2 CLEAVABLE LINKERS

11.2.1 PEPTIDE BASED

11.2.2 ACID SENSITIVE OR ACID LABILE

11.2.3 GLUTATHIONE SENSITIVE DISULFIDE

11.3 NON CLEAVABLE LINKERS

12 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT

12.1 OVERVIEW

12.2 DNA DAMAGING AGENTS

12.2.1 CAMPTOTHECIN

12.2.2 CALICHEAMICIN

12.2.3 PYRROLOBENZODIAZEPINES

12.3 MICROTUBULE DISRUPTING AGENTS

12.3.1 AURISTATIN

12.3.2 MAYTANSINOIDS

13 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY

13.1 OVERVIEW

13.2 PEPTIDE LINKERS

13.3 THIOETHER LINKERS

13.4 HYDRAZONE LINKERS

13.5 DISULFIDE LINKERS

14 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY

14.1 OVERVIEW

14.2 SITE-SPECIFIC CONJUGATION

14.3 CHEMICAL CONJUGATION

15 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION

15.1 OVERVIEW

15.2 BREAST CANCER

15.3 BLOOD CANCER (LEUKEMIA, LYMPHOMA)

15.4 LUNG CANCER

15.5 GYNECOLOGICAL CANCER

15.6 GASTROINTESTINAL CANCER

15.7 GENITOURINARY CANCER

15.8 OTHERS

16 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.3 SPECIALTY CENTER

16.4 CLINICS

16.5 AMBULATORY CENTERS

16.6 HOME HEALTHCARE

16.7 OTHERS

17 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 DIRECT TENDERS

17.3 RETAIL SALES

17.3.1 HOSPITAL PHARMACY

17.3.2 RETAIL PHARMACY

17.3.3 ONLINE PHARMACY

17.4 OTHERS

18 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION

18.1 OVERVIEW

18.2 NORTH AMERICA

18.2.1 U.S

18.2.2 CANADA

18.2.3 MEXICO

18.3 EUROPE

18.3.1 GERMANY

18.3.2 U.K

18.3.3 FRANCE

18.3.4 ITALY

18.3.5 SPAIN

18.3.6 RUSSIA

18.3.7 BELGIUM

18.3.8 NETHERLANDS

18.3.9 SWITZERLAND

18.3.10 AUSTRIA

18.3.11 IRELAND

18.3.12 POLAND

18.3.13 NORWAY

18.3.14 HUNGARY

18.3.15 LITHUANIA

18.3.16 REST OF EUROPE

18.4 ASIA-PACIFIC

18.4.1 JAPAN

18.4.2 CHINA

18.4.3 INDIA

18.4.4 AUSTRALIA

18.4.5 SINGAPORE

18.4.6 REST OF ASIA-PACIFIC

18.5 SOUTH AMERICA

18.5.1 BRAZIL

18.5.2 ARGENTINA

18.5.3 REST OF SOUTH AMERICA

18.6 MIDDLE EAST AND AFRICA

18.6.1 SAUDI ARABIA

18.6.2 U.A.E

18.6.3 ISRAEL

18.6.4 SOUTH AFRICA

18.6.5 REST OF MIDDLE EAST AND AFRICA

19 GLOBAL ANTIBODY DRUG CONJUGATES (ADC): COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: GLOBAL

19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

19.3 COMPANY SHARE ANALYSIS: EUROPE

19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20 SWOT ANALYSIS

21 COMPANY PROFILES

21.1 DAIICHI SANKYO, INC.

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 PRODUCT PORTFOLIO

21.1.4 RECENT DEVELOPMENT

21.2 F. HOFFMANN-LA ROCHE LTD

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 PRODUCT PORTFOLIO

21.2.4 RECENT DEVELOPMENT

21.3 GILEAD SCIENCES, INC.

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE

21.3.3 PRODUCT PORTFOLIO

21.3.4 RECENT DEVELOPMENT

21.4 ASTELLAS PHARMA INC.

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 PRODUCT PORTFOLIO

21.4.4 RECENT DEVELOPMENT

21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 PRODUCT PORTFOLIO

21.5.4 RECENT DEVELOPMENT

21.6 ABBVIE INC.

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 ADC THERAPEUTICS SA

21.7.1 6.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENT

21.8 AMGEN, INC.

21.8.1 COMPANY SNAPSHOT

21.8.2 REVENUE ANALYSIS

21.8.3 PRODUCT PORTFOLIO

21.8.4 RECENT DEVELOPMENT

21.9 ASTRAZENECA

21.9.1 COMPANY SNAPSHOT

21.9.2 REVENUE ANALYSIS

21.9.3 PRODUCT PORTFOLIO

21.9.4 RECENT DEVELOPMENT

21.1 BAYER

21.10.1 COMPANY SNAPSHOT

21.10.2 REVENUE ANALYSIS

21.10.3 PRODUCT PORTFOLIO

21.10.4 RECENT DEVELOPMENT

21.11 BYONDIS

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENT

21.12 EISAI INC

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 GSK PLC

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENT

21.14 JOHNSON & JOHNSON SERVICES, INC.

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENT

21.15 OXFORD BIOTHERAPEUTICS

21.15.1 COMPANY SNAPSHOT

21.15.2 PRODUCT PORTFOLIO

21.15.3 RECENT DEVELOPMENT

21.16 PFIZER INC.

21.16.1 COMPANY SNAPSHOT

21.16.2 REVENUE ANALYSIS

21.16.3 PRODUCT PORTFOLIO

21.16.4 RECENT UPDATES

21.17 REMEGEN

21.17.1 COMPANY SNAPSHOT

21.17.2 PRODUCT PORTFOLIO

21.17.3 RECENT DEVELOPMENTS

21.18 SANOFI

21.18.1 COMPANY SNAPSHOT

21.18.2 REVENUE ANALYSIS

21.18.3 PRODUCT PORTFOLIO

21.18.4 RECENT DEVELOPMENT

21.19 SUTRO BIOPHARMA, INC.

21.19.1 COMPANY SNAPSHOT

21.19.2 REVENUE ANALYSIS

21.19.3 PRODUCT PORTFOLIO

21.19.4 RECENT UPDATES

22 QUESTIONNAIRE

23 RELATED REPORTS

List of Table

TABLE 1 PROJECTED PRICE CHANGE (2024–2030)

TABLE 2 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 4 GLOBAL ENHERTU IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL KADCYLA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL TRODELVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL POLIVY IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL ADCETRIS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL PADCEV IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL BESPONSA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL ELAHERE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL ZYLONTA IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL MYLOTARG IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL TIVDAK IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 17 GLOBAL HER2 RECEPTOR IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 18 GLOBAL TROP-2 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL CD79B IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL CD30 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL NECTIN 4 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL CD22 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL CD19 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL CD33 IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL TISSUE FACTORS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL THIRD GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL SECOND GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL FOURTH GENERATION ADCS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL FIRST GENERATION ADCS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL NON CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL PEPTIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL THIOETHER LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL HYDRAZONE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL DISULFIDE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 46 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 47 GLOBAL SITE-SPECIFIC CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 GLOBAL CHEMICAL CONJUGATION IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 49 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 50 GLOBAL BREAST CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 51 GLOBAL BLOOD CANCER (LEUKEMIA, LYMPHOMA) IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 52 GLOBAL LUNG CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 53 GLOBAL GYNECOLOGICAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 54 GLOBAL GASTROINTESTINAL CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 55 GLOBAL GENITOURINARY CANCER IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 56 GLOBAL OTHERS IN OPHTHALMOLOGY MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 57 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 58 GLOBAL HOSPITALS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 59 GLOBAL SPECIALTY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 60 GLOBAL CLINICS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 61 GLOBAL AMBULATORY CENTERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 62 GLOBAL HOME HEALTHCARE IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 63 GLOBAL OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 64 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 65 GLOBAL DIRECT TENDERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 66 GLOBAL RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 67 GLOBAL RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 68 GLOBAL OTHERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 69 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 71 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 72 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 73 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 74 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 75 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 76 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 77 NORTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 78 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 79 NORTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 80 NORTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 81 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 82 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 83 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 84 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 85 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 86 NORTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 87 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 88 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 89 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 90 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 91 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 92 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 93 U.S. CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 94 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 95 U.S. DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 96 U.S. MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 97 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 98 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 99 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 100 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 101 U.S. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 102 U.S. RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 103 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 104 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 105 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 106 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 107 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 108 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 109 CANADA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 110 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 111 CANADA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 112 CANADA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 113 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 114 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 115 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 116 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 117 CANADA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 118 CANADA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 119 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 120 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 121 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 122 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 123 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 124 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 125 MEXICO CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 126 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 127 MEXICO DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 128 MEXICO MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 129 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 130 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 131 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 132 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 133 MEXICO ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 134 MEXICO RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 135 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 136 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 137 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 138 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 139 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 140 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 141 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 142 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 143 EUROPE CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 144 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 145 EUROPE DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 146 EUROPE MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 147 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 148 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 149 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 150 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 151 EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 152 EUROPE RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 153 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 154 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 155 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 156 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 157 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 158 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 159 GERMANY CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 160 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 161 GERMANY DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 162 GERMANY MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 163 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 164 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 165 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 166 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 167 GERMANY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 168 GERMANY RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 169 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 170 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 171 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 172 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 173 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 174 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 175 U.K. CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 176 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 177 U.K. DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 178 U.K. MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 179 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 180 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 181 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 182 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 183 U.K. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 184 U.K. RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 185 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 186 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 187 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 188 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 189 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 190 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 191 FRANCE CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 192 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 193 FRANCE DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 194 FRANCE MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 195 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 196 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 197 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 198 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 199 FRANCE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 200 FRANCE RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 201 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 202 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 203 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 204 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 205 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 206 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 207 ITALY CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 208 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 209 ITALY DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 210 ITALY MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 211 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 212 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 213 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 214 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 215 ITALY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 216 ITALY RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 217 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 218 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 219 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 220 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 221 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 222 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 223 SPAIN CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 224 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 225 SPAIN DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 226 SPAIN MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 227 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 228 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 229 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 230 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 231 SPAIN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 232 SPAIN RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 233 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 234 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 235 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 236 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 237 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 238 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 239 RUSSIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 240 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 241 RUSSIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 242 RUSSIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 243 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 244 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 245 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 246 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 247 RUSSIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 248 RUSSIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 249 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 250 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 251 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 252 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 253 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 254 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 255 BELGIUM CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 256 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 257 BELGIUM DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 258 BELGIUM MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 259 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 260 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 261 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 262 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 263 BELGIUM ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 264 BELGIUM RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 265 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 266 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 267 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 268 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 269 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 270 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 271 NETHERLANDS CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 272 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 273 NETHERLANDS DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 274 NETHERLANDS MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 275 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 276 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 277 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 278 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 279 NETHERLANDS ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 280 NETHERLANDS RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 281 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 282 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 283 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 284 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 285 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 286 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 287 SWITZERLAND CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 288 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 289 SWITZERLAND DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 290 SWITZERLAND MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 291 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 292 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 293 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 294 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 295 SWITZERLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 296 SWITZERLAND RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 297 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 298 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 299 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 300 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 301 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 302 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 303 AUSTRIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 304 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 305 AUSTRIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 306 AUSTRIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 307 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 308 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 309 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 310 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 311 AUSTRIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 312 AUSTRIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 313 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 314 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 315 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 316 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 317 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 318 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 319 IRELAND CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 320 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 321 IRELAND DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 322 IRELAND MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 323 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 324 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 325 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 326 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 327 IRELAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 328 IRELAND RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 329 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 330 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 331 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 332 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 333 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 334 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 335 POLAND CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 336 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 337 POLAND DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 338 POLAND MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 339 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 340 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 341 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 342 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 343 POLAND ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 344 POLAND RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 345 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 346 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 347 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 348 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 349 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 350 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 351 NORWAY CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 352 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 353 NORWAY DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 354 NORWAY MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 355 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 356 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 357 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 358 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 359 NORWAY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 360 NORWAY RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 361 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 362 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 363 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 364 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 365 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 366 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 367 HUNGARY CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 368 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 369 HUNGARY DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 370 HUNGARY MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 371 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 372 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 373 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 374 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 375 HUNGARY ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 376 HUNGARY RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 377 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 378 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 379 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 380 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 381 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 382 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 383 LITHUANIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 384 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 385 LITHUANIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 386 LITHUANIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 387 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 388 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 389 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 390 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 391 LITHUANIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 392 LITHUANIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 393 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 394 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 395 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 396 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 397 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 398 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 399 REST OF EUROPE CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 400 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 401 REST OF EUROPE DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 402 REST OF EUROPE MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 403 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 404 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 405 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 406 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 407 REST OF EUROPE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 408 REST OF EUROPE RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 409 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 410 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 411 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 412 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 413 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 414 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 415 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 416 ASIA-PACIFIC CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 417 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 418 ASIA-PACIFIC DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 419 ASIA-PACIFIC MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 420 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 421 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 422 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 423 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 424 ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 425 ASIA-PACIFIC RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 426 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 427 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 428 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 429 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 430 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 431 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 432 JAPAN CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 433 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 434 JAPAN DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 435 JAPAN MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 436 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 437 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 438 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 439 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 440 JAPAN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 441 JAPAN RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 442 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 443 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 444 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 445 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 446 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 447 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 448 CHINA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 449 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 450 CHINA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 451 CHINA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 452 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 453 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 454 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 455 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 456 CHINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 457 CHINA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 458 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 459 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 460 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 461 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 462 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 463 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 464 INDIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 465 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 466 INDIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 467 INDIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 468 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 469 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 470 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 471 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 472 INDIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 473 INDIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 474 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 475 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 476 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 477 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 478 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 479 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 480 AUSTRALIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 481 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 482 AUSTRALIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 483 AUSTRALIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 484 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 485 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 486 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 487 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 488 AUSTRALIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 489 AUSTRALIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 490 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 491 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 492 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 493 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 494 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 495 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 496 SINGAPORE CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 497 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 498 SINGAPORE DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 499 SINGAPORE MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 500 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 501 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 502 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 503 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 504 SINGAPORE ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 505 SINGAPORE RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 506 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 507 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 508 REST OF ASIA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 509 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 510 341

TABLE 511 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 512 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 513 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 514 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 515 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 516 SOUTH AMERICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 517 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 518 SOUTH AMERICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 519 SOUTH AMERICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 520 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 521 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 522 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 523 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 524 SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 525 SOUTH AMERICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 526 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 527 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 528 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 529 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 530 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 531 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 532 BRAZIL CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 533 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 534 BRAZIL DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 535 BRAZIL MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 536 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 537 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 538 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 539 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 540 BRAZIL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 541 BRAZIL RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 542 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 543 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 544 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 545 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 546 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 547 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 548 ARGENTINA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 549 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 550 ARGENTINA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 551 ARGENTINA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 552 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 553 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 554 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 555 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 556 ARGENTINA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 557 ARGENTINA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 558 REST OF SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 559 REST OF SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 560 REST OF SOUTH AMERICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 561 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 562 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 563 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 564 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 565 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 566 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 567 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 568 MIDDLE EAST AND AFRICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 569 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 570 MIDDLE EAST AND AFRICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 571 MIDDLE EAST AND AFRICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 572 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 573 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 574 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 575 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 576 MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 577 MIDDLE EAST AND AFRICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 578 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 579 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 580 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 581 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 582 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 583 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 584 SAUDI ARABIA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 585 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 586 SAUDI ARABIA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 587 SAUDI ARABIA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 588 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 589 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 590 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 591 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 592 SAUDI ARABIA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 593 SAUDI ARABIA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 594 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 595 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 596 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 597 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 598 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 599 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 600 U.A.E. CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 601 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 602 U.A.E. DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 603 U.A.E. MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 604 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 605 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 606 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 607 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 608 U.A.E. ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 609 U.A.E. RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 610 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 611 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 612 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 613 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 614 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 615 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 616 ISRAEL CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 617 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 618 ISRAEL MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 619 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 620 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 621 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 622 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 623 ISRAEL ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 624 ISRAEL RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 625 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 626 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 627 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

TABLE 628 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIGEN COMPONENT, 2022-2031 (USD MILLION)

TABLE 629 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY ANTIBODY COMPONENT, 2022-2031 (USD MILLION)

TABLE 630 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKERS COMPONENT, 2022-2031 (USD MILLION)

TABLE 631 SOUTH AFRICA CLEAVABLE LINKERS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 632 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2022-2031 (USD MILLION)

TABLE 633 SOUTH AFRICA DNA DAMAGING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 634 SOUTH AFRICA MICROTUBULE DISRUPTING AGENTS IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY COMPONENT, 2022-2031 (USD MILLION)

TABLE 635 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY LINKER TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 636 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY CONJUGATION TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 637 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY INDICATION, 2022-2031 (USD MILLION)

TABLE 638 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 639 SOUTH AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 640 SOUTH AFRICA RETAIL SALES IN ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 641 REST OF MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (USD MILLION)

TABLE 642 REST OF MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (VOLUME IN UNITS)

TABLE 643 REST OF MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES (ADC) MARKET, BY PRODUCT, 2022-2031 (ASP)

List of Figure

FIGURE 1 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION

FIGURE 2 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: SEGMENTATION

FIGURE 11 EXECUTIVE SUMMARY

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 RISING INCIDENCE OF CANCER IS DRIVING THE GROWTH OF THE GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET FROM 2024 TO 2031

FIGURE 14 THE PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET IN 2024 AND 2031

FIGURE 15 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR ANTIBODY DRUG CONJUGATES (ADC) MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 17 DROC

FIGURE 18 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2023

FIGURE 19 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, 2024-2031 (USD MILLION)

FIGURE 20 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, CAGR (2024-2031)

FIGURE 21 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 22 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2023

FIGURE 23 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, 2024-2031 (USD MILLION)

FIGURE 24 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, CAGR (2024-2031)

FIGURE 25 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIGEN COMPONENT, LIFELINE CURVE

FIGURE 26 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2023

FIGURE 27 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, 2024-2031 (USD MILLION)

FIGURE 28 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, CAGR (2024-2031)

FIGURE 29 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY ANTIBODY COMPONENT, LIFELINE CURVE

FIGURE 30 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2023

FIGURE 31 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, 2024-2031 (USD MILLION)

FIGURE 32 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, CAGR (2024-2031)

FIGURE 33 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKERS COMPONENT, LIFELINE CURVE

FIGURE 34 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2023

FIGURE 35 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, 2024-2031 (USD MILLION)

FIGURE 36 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, CAGR (2024-2031)

FIGURE 37 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CYTOTOXIC PAYLOADS OR WARHEADS COMPONENT, LIFELINE CURVE

FIGURE 38 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2023

FIGURE 39 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, 2024-2031 (USD MILLION)

FIGURE 40 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, CAGR (2024-2031)

FIGURE 41 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY LINKER TECHNOLOGY, LIFELINE CURVE

FIGURE 42 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2023

FIGURE 43 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, 2024-2031 (USD MILLION)

FIGURE 44 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, CAGR (2024-2031)

FIGURE 45 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY CONJUGATION TECHNOLOGY, LIFELINE CURVE

FIGURE 46 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2023

FIGURE 47 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, 2024-2031 (USD MILLION)

FIGURE 48 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, CAGR (2024-2031)

FIGURE 49 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 50 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2023

FIGURE 51 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 52 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, CAGR (2024-2031)

FIGURE 53 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY END USER, LIFELINE CURVE

FIGURE 54 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 55 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 56 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 57 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 58 GLOBAL ANTIBODY DRUG CONJUGATES (ADC) MARKET: SNAPSHOT (2023)

FIGURE 59 GLOBAL ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)

FIGURE 60 NORTH AMERICA ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)

FIGURE 61 EUROPE ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)

FIGURE 62 AISA-PACIFIC ANTIBODY DRUG CONJUGATES (ADC): COMPANY SHARE 2023 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Global Antibody Drug Conjugates (ADC) Market size was valued at USD 9,330.71 million in 2023.
The Global Antibody Drug Conjugates (ADC) Market is projected to grow at a CAGR of 15.6% from 2024 to 2031.
The rising prevalence of cancer and Advances in antibody-drug conjugate (ADC) technology are the major growth driving factors.
DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd (Genetech), Gilead Sciences, Inc., Astellas Pharma Inc., Takeda, Pfizer Inc., Abbvie, ADC Therapeutics, Amgen, Inc., AstraZeneca, Bayer, Byondis, EISAI INC, GSK plc, Johnson & Johnson Services, Inc., Oxford BioTherapeutics, Remegen, Sanofi, Sutra Biopharmaamong others.
The countries covered in the market are North America, South America, Asia Pacific , Europe and Middle east and Africa .

Browse Related Pages

Banner
Testimonial
Image
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Image
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Image
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Image
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Image
Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Image
Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

Image
COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Image
Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Image
Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Image
Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Image
Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Image
Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Image
Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Image
Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Image
Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Image
Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future